AMGEN at the American Heart Association's (AHA) Scientific Sessions 2022

Welcome to the Amgen Medical Virtual Exhibit

Cardiometabolic Pipeline

PROFICIO Clinical Development Program-Introducing VESALIUS-CV

Evolocumab PROFICIO Program and Ongoing Trials Book

Learn about PROFICIO, Amgen’s program of clinical studies of evolocumab, including VESALIUS-CV, a global initiative exploring the potential of evolocumab for the prevention of first CV events. This is an investigational study. Evolocumab is not indicated for this intended use.


Please note: Some of the information on this page may pertain to investigational drugs.